Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Wang, Zijun; Muecksch, Frauke; Schaefer-Babajew, Dennis; Finkin, Shlomo; Viant, Charlotte; Gaebler, Christian; Hoffmann, Hans Heinrich; Barnes, Christopher O.; Cipolla, Melissa; Ramos, Víctor; Oliveira, Thiago Y.; Cho, Alice; Schmidt, Fabian; DaSilva, Justin; Bednarski, Eva; Aguado, Lauren C.; Yee, Jim; Daga, Mridushi; Turroja, Martina; Millard, Katrina G.; Janković, Mila; Gazumyan, Anna; Zhao, Zhen; Rice, Charles M.; Bieniasz, Paul D.; Caskey, Marina; Hatziioannou, Théodora; Nussenzweig, Michel C.

doi:10.1038/s41586-021-03696-9

Cited by 635 publications

(743 citation statements)

References 55 publications

(156 reference statements)

Supporting

Mentioning

645

Contrasting

Unclassified

Order By: Relevance

“…In agreement with previous studies, levels of IgG serum antibodies elicited by the mRNA vaccine were significantly higher than those of convalescent individuals 11,15,16 and inversely correlated with age 17 (Fig 3). In the month following the second BNT162b2 dose, older individuals had lower antibody levels in the seroconversion phase, followed by an earlier and steeper decline compared to younger age-groups (Fig 5).…”

Section: Discussionsupporting

confidence: 92%

Antibody response to SARS-CoV-2 infection and BNT162b2 vaccine in Israel

Shapira

Hamad²,

Weiner

et al. 2021

Preprint

View full text Add to dashboard Cite

Neutralizing antibodies targeting the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) block viral entry to host cells, preventing disease and further spread of the pathogen. The presence of SARS-CoV-2 antibodies in serum is a reliable indicator of infection, used epidemiologically to estimate the prevalence of infection and clinically as a measurement of an antigen-specific immune response. In this study, we analyzed serum Spike protein-specific IgG antibodies from 26,170 samples, including convalescent individuals who had coronavirus disease 2019 (COVID-19) and recipients of the BNT162b2 vaccine. We find distinct serological patterns in COVID-19 convalescent and vaccinated individuals, correlated with age and gender and the presence symptoms.

show abstract

Section: Discussionsupporting

confidence: 92%

Antibody response to SARS-CoV-2 infection and BNT162b2 vaccine in Israel

Shapira

Hamad²,

Weiner

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Although it is generally accepted that recovered individuals do not benefit from the second dose of the vaccine (Wang et al 2021;Mazzoni et al 2021;Krammer et al 2021;Goel et al 2021;Ebinger et al 2021;Camara et al 2021), donor R10 clearly exhibited antibody boost due to the second dose of BNT162b2. Overall, anti-RBD (Fig.…”

Section: Resultsmentioning

confidence: 98%

SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells

Minervina

Pogorelyy

Kirk

et al. 2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 mRNA vaccines, including Pfizer/Biontech BNT162b2, were shown to be effective for COVID-19 prevention, eliciting both robust antibody responses in naive individuals and boosting pre-existing antibody levels in SARS-CoV-2-recovered individuals. However, the magnitude, repertoire, and phenotype of epitope-specific T cell responses to this vaccine, and the effect of vaccination on pre-existing T cell memory in SARS-CoV-2 convalescent patients, are still poorly understood. Thus, in this study we compared epitope-specific T cells elicited after natural SARS-CoV-2 infection, and vaccination of both naive and recovered individuals. We collected peripheral blood mononuclear cells before and after BNT162b2 vaccination and used pools of 18 DNA-barcoded MHC-class I multimers, combined with scRNAseq and scTCRseq, to characterize T cell responses to several immunodominant epitopes, including a spike-derived epitope cross-reactive to common cold coronaviruses. Comparing responses after infection or vaccination, we found that T cells responding to spike-derived epitopes show similar magnitudes of response, memory phenotypes, TCR repertoire diversity, and αβTCR sequence motifs, demonstrating the potency of this vaccination platform. Importantly, in COVID-19-recovered individuals receiving the vaccine, pre-existing spike-specific memory cells showed both clonal expansion and a phenotypic shift towards more differentiated CCR7-CD45RA+ effector cells. In-depth analysis of T cell receptor repertoires demonstrates that both vaccination and infection elicit largely identical repertoires as measured by dominant TCR motifs and receptor breadth, indicating that BNT162b2 vaccination largely recapitulates T cell generation by infection for all critical parameters. Thus, BNT162b2 vaccination elicits potent spike-specific T cell responses in naive individuals and also triggers the recall T cell response in previously infected individuals, further boosting spike-specific responses but altering their differentiation state. Overall, our study demonstrates the potential of mRNA vaccines to induce, maintain, and shape T cell memory through vaccination and revaccination.

show abstract

“…Affinity was measured by Biolayer interferometry assays (Wang et al, 2021a). An Octet Red instrument (ForteBio) was used at 30 C with shaking at 1,000 rpm The kinetic analysis using protein A biosensor (ForteBio 18-5010) was performed as follows: (1) baseline: 60sec immersion in buffer.…”

Section: Affinity Measurementsmentioning

confidence: 99%